Molaie Soheila, Ghaffarifar Fatemeh, Dalimi Abdohosein, Zuhair Mohammad Hassan, Sharifi Zohreh
Department of Parasitology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Deputy of Research, Ardabil University of Medical Sciences, Ardabil, Iran.
Iran J Basic Med Sci. 2019 Feb;22(2):146-153. doi: 10.22038/ijbms.2018.31124.7504.
Because leishmaniasis is related to the impaired functioning of T-cells, the use of an immunomodulator can increase the efficacy of antileishmanial therapy in visceral leishmaniasis. In this study, we used shark cartilage extract with artemisinin and glucantime against visceral leishmaniasis in BALB/c mice, and evaluated the synergistic therapeutic effect.
The culturing method and quantitative real-time PCR by using the kDNA gene was used to detect parasite loads in the spleen and liver. INF-γ and IL-4 cytokine levels and survival rates were assayed.
The drug therapy with target drugs reduced parasite burden in the spleen and liver significantly. Although parasite burden was lower in the artemisinin treated group than in the glucantime treated group (<0.05). The mice survival rate records, throughout the experimental period, showed highly significant survival rates in the test groups compared to the control group (<0.001). The results of cytokine assay in mice treated with glucantime-shark cartilage extract combination indicated significant increases of IFNγ and IL-4 (<0.05). Although the increase of IFNγ was more notable than IL-4. The synergistic therapeutic effect is shown in all groups except in the group treated with shark cartilage extract-artemisinin combination. The IFN-γ in glucantime-shark cartilage extract combination treated group was higher than in other groups (<0.05). The survival rate in this group was more than in other groups too (<0.05).
Combination therapy with shark cartilage extract as an immunomodulator can increase antileishmanial effects of antimony drugs in VL treatment.
由于利什曼病与T细胞功能受损有关,使用免疫调节剂可提高内脏利什曼病抗利什曼治疗的疗效。在本研究中,我们使用鲨鱼软骨提取物联合青蒿素和葡糖胺锑钠治疗BALB/c小鼠的内脏利什曼病,并评估其协同治疗效果。
采用培养法和基于kDNA基因的定量实时PCR检测脾脏和肝脏中的寄生虫载量。检测INF-γ和IL-4细胞因子水平及生存率。
使用目标药物进行药物治疗可显著降低脾脏和肝脏中的寄生虫负荷。虽然青蒿素治疗组的寄生虫负荷低于葡糖胺锑钠治疗组(<0.05)。在整个实验期间,各试验组小鼠的生存率记录显示,与对照组相比有极显著的生存率差异(<0.001)。葡糖胺锑钠-鲨鱼软骨提取物联合治疗小鼠的细胞因子检测结果表明,IFNγ和IL-4显著增加(<0.05)。虽然IFNγ的增加比IL-4更显著。除鲨鱼软骨提取物-青蒿素联合治疗组外,所有组均显示出协同治疗效果。葡糖胺锑钠-鲨鱼软骨提取物联合治疗组的IFN-γ高于其他组(<0.05)。该组的生存率也高于其他组(<0.05)。
以鲨鱼软骨提取物作为免疫调节剂的联合治疗可提高锑剂药物在VL治疗中的抗利什曼效果。